FDA Partial Clinical Hold on BHV-7000 Epilepsy Trials Triggers Sharp Selloff and Investigation

What happened

Biohaven disclosed that the FDA placed a partial clinical hold on new-patient enrollment in its BHV-7000/opakalimab epilepsy trials, causing shares to fall nearly 15% in one session. The hold halts enrollment but allows existing patients to continue treatment, suggesting a safety or data integrity issue that must be addressed before new patients can be added. This setback compounds the company's existing distress following the troriluzole SCA complete response letter, heavy cash burn, and negative equity. A plaintiff law firm has announced a pending investigation into potential securities law violations, adding legal risk. The BHV-7000 epilepsy program was the central value driver in Biohaven's base case, so any delay or negative signal directly undermines the investment thesis.

Implication

Investors should reduce positions or avoid new purchases until the specific reasons for the hold and the timeline for resolution are clarified, as the delay could push back the pivotal readout and increase cash burn. The hold raises the possibility of undisclosed safety concerns in the epilepsy program, which could signal broader issues with the Kv7 platform. Given Biohaven's precarious financial state, with only about 12–18 months of runway and negative equity, prolonged enrollment delays may force dilutive financing or more severe pipeline cuts. The investigation notice adds another layer of risk, though it may not lead to material damages. Overall, the risk/reward has deteriorated; the base case value should be lowered, and the bear case probability increased, making the stock only suitable for speculative investors with high risk tolerance.

Thesis delta

The thesis previously hinged on BHV-7000 delivering positive epilepsy data in 1H 2026, but the clinical hold introduces regulatory and timeline risk that directly lowers the probability of that outcome. The bear case (30% probability, $7 value) becomes more likely, while the bull case (25%, $20) recedes; the base case ($14) may move downward if the hold persists. Conviction drops from potential buy to neutral/avoid until clarity emerges, with re-assessment contingent on FDA resolution and subsequent data.